Lexeo Therapeutics (LXEO) Assets (2022 - 2026)

Lexeo Therapeutics' Assets history runs 5 years deep, the most recent figure standing at $250.4 million for Q1 2026.

• In Q1 2026, Assets rose 99.19% year-over-year to $250.4 million; the TTM figure through Mar 2026 stood at $250.4 million (up 99.19% YoY), while the FY2025 annual figure was $268.7 million, up 82.85% from the prior year.
• Assets came in at $250.4 million for Q1 2026 at Lexeo Therapeutics, down from $268.7 million in the prior quarter.
• In the past five years, Assets ranged from a high of $268.7 million in Q4 2025 to a low of $54.7 million in Q3 2023.
• A 5-year average of $165.2 million and a median of $160.4 million in 2024 frame the typical range for Assets.
• Across the five-year window, Assets soared 217.71% in 2024 and sank 41.05% in 2025, its largest moves.
• Lexeo Therapeutics' Assets stood at $97.1 million in 2022, then soared by 44.02% to $139.8 million in 2023, then increased by 5.1% to $146.9 million in 2024, then soared by 82.85% to $268.7 million in 2025, then retreated by 6.82% to $250.4 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $250.4 million, $268.7 million, and $143.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison